MARKET

REPH

REPH

Recro Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.88
+0.09
+0.51%
After Hours: 16.88 0 0.00% 16:00 02/21 EST
OPEN
16.85
PREV CLOSE
16.80
HIGH
17.21
LOW
16.59
VOLUME
187.88K
TURNOVER
--
52 WEEK HIGH
19.21
52 WEEK LOW
4.957
MARKET CAP
383.69M
P/E (TTM)
-7.2437
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of REPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average REPH stock price target is 21.50 with a high estimate of 23.00 and a low estimate of 19.00.

EPS

REPH News

More
  • How Should Investors React To Recro Pharma, Inc.'s (NASDAQ:REPH) CEO Pay?
  • Simply Wall St. · 1d ago
  • Laughing Water Capital Year-End 2019 Letter
  • Seeking Alpha - Article · 2d ago
  • Tyro Capital Management 2019 Annual Commentary
  • Seeking Alpha - Article · 3d ago
  • It's a big week for Malvern company's twice-rejected drug and the 60 jobs hinging on FDA approval
  • American City Business Journals · 3d ago

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About REPH

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
More

Webull offers kinds of Recro Pharma Inc stock information, including NASDAQ:REPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPH stock news, and many more online research tools to help you make informed decisions.